![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Qiuzhen Liang, Haibin Xiang, Xinyu Li, Chunxia Luo, Xuehong Ma, Wenhui Zhao, Jiangtao Chen, Zheng Tian, Xinxia Li & Xinghua Song. (2020) Development of Rifapentine-Loaded PLGA-Based Nanoparticles: In vitro Characterisation and in vivo Study in Mice. International Journal of Nanomedicine 15, pages 7491-7507.
Read now
Read now
Eric F. Egelund & Charles A. Peloquin. (2016) Rifapentine for the treatment of latent tuberculosis. Expert Review of Clinical Pharmacology 9:10, pages 1253-1261.
Read now
Read now
Ning-Kui Niu, Juan-Juan Yin, Yin-Xue Yang, Zi-Li Wang, Zhi-Wei Zhou, Zhi-Xu He, Xiao-Wu Chen, Xueji Zhang, Wei Duan, Tianxin Yang & Shu-Feng Zhou. (2015) Novel targeting of PEGylated liposomes for codelivery of TGF-β1 siRNA and four antitubercular drugs to human macrophages for the treatment of mycobacterial infection: a quantitative proteomic study. Drug Design, Development and Therapy 9, pages 4441-4470.
Read now
Read now
Jun Wu, Yi Zuo, Yunjiu Hu, Jian Wang, Jidong Li, Bo Qiao & Dianming Jiang. (2015) Development and in vitro characterization of drug delivery system of rifapentine for osteoarticular tuberculosis. Drug Design, Development and Therapy 9, pages 1359-1366.
Read now
Read now
Articles from other publishers (19)
Rakhi Yadav, Dilkhush Meena, Kavita Singh, Rajdeep Tyagi, Yogesh Yadav & Ram Sagar. (2023) Recent advances in the synthesis of new benzothiazole based anti-tubercular compounds. RSC Advances 13:32, pages 21890-21925.
Crossref
Crossref
Yesha B. Shah, Priya S. Mistry, Tejas M. Dhameliya, Ketan M. Ranch, Sai H. S. Boddu, Shery Jacob, B. Mahalakshmi & Jwala Renukuntla. 2023. Tubercular Drug Delivery Systems. Tubercular Drug Delivery Systems
59
77
.
Heejun Park, Eun-Sol Ha & Min-Soo Kim. (2021) Surface modification strategies for high-dose dry powder inhalers. Journal of Pharmaceutical Investigation 51:6, pages 635-668.
Crossref
Crossref
Chukwuebuka Egbuna, Shahira M. Ezzat, Habibu Tijjani & Vijay K. Srivastav. 2019. Phytochemistry: An in-silico and in-vitro Update. Phytochemistry: An in-silico and in-vitro Update
23
55
.
Regina Scherließ & Christian Etschmann. (2018) DPI formulations for high dose applications – Challenges and opportunities. International Journal of Pharmaceutics 548:1, pages 49-53.
Crossref
Crossref
Zubair Shanib Bhat, Muzafar Ahmad Rather, Mubashir Maqbool & Zahoor Ahmad. (2018) Drug targets exploited in Mycobacterium tuberculosis: Pitfalls and promises on the horizon. Biomedicine & Pharmacotherapy 103, pages 1733-1747.
Crossref
Crossref
Hussam W. Al-Humadi, Rafal J. Al-Saigh & Ahmed W. Al-Humadi. (2017) Addressing the Challenges of Tuberculosis: A Brief Historical Account. Frontiers in Pharmacology 8.
Crossref
Crossref
Shardendu K. Mishra, Garima Tripathi, Navneet Kishore, Rakesh K. Singh, Archana Singh & Vinod K. Tiwari. (2017) Drug development against tuberculosis: Impact of alkaloids. European Journal of Medicinal Chemistry 137, pages 504-544.
Crossref
Crossref
Yuwu Liu & Dianming Jiang. (2017) Effect of bone-like hydroxyapatite/poly amino acid loaded with rifapentine microspheres on bone and joint tuberculosis in vitro. Cell Biology International 41:4, pages 369-373.
Crossref
Crossref
Yuwu Liu, Jiming Zhu & Dianming Jiang. (2017) Release characteristics of bone-like hydroxyapatite/poly amino acid loaded with rifapentine microspheres in vivo. Molecular Medicine Reports 16:2, pages 1425-1430.
Crossref
Crossref
Thaigarajan Parumasivam, Anneliese S. Ashhurst, Gayathri Nagalingam, Warwick J. Britton & Hak-Kim Chan. (2016) Inhalation of Respirable Crystalline Rifapentine Particles Induces Pulmonary Inflammation. Molecular Pharmaceutics 14:1, pages 328-335.
Crossref
Crossref
Thaigarajan Parumasivam, Sharon S. Y. Leung, Patricia Tang, Citterio Mauro, Warwick Britton & Hak-Kim Chan. (2016) The Delivery of High-Dose Dry Powder Antibiotics by a Low-Cost Generic Inhaler. The AAPS Journal 19:1, pages 191-202.
Crossref
Crossref
Jennifer Wong, Maurizio Ricci & Hak-Kim Chan. 2016. Drug Delivery Systems for Tuberculosis Prevention and Treatment. Drug Delivery Systems for Tuberculosis Prevention and Treatment
161
196
.
P. Bernard Fourie & Richard Hafner. 2016. Drug Delivery Systems for Tuberculosis Prevention and Treatment. Drug Delivery Systems for Tuberculosis Prevention and Treatment
400
414
.
T. Parumasivam, J.G.Y. Chan, A. Pang, D.H. Quan, J.A. Triccas, W.J. Britton & H.K. Chan. (2016) In vitro evaluation of novel inhalable dry powders consisting of thioridazine and rifapentine for rapid tuberculosis treatment. European Journal of Pharmaceutics and Biopharmaceutics 107, pages 205-214.
Crossref
Crossref
Thaigarajan Parumasivam, Rachel Yoon Kyung Chang, Sharif Abdelghany, Tian Tian Ye, Warwick John Britton & Hak-Kim Chan. (2016) Dry powder inhalable formulations for anti-tubercular therapy. Advanced Drug Delivery Reviews 102, pages 83-101.
Crossref
Crossref
Thaigarajan Parumasivam, Sharon S.Y. Leung, Diana Huynh Quan, Jamie A. Triccas, Warwick J. Britton & Hak-Kim Chan. (2016) Rifapentine-loaded PLGA microparticles for tuberculosis inhaled therapy: Preparation and in vitro aerosol characterization. European Journal of Pharmaceutical Sciences 88, pages 1-11.
Crossref
Crossref
Joseph Mwanzia Nguta, Regina Appiah-Opong, Alexander K. Nyarko, Dorothy Yeboah-Manu & Phyllis G.A. Addo. (2015) Current perspectives in drug discovery against tuberculosis from natural products. International Journal of Mycobacteriology 4:3, pages 165-183.
Crossref
Crossref
Giovanna Riccardi & Maria Rosalia Pasca. (2014) Trends in discovery of new drugs for tuberculosis therapy. The Journal of Antibiotics 67:9, pages 655-659.
Crossref
Crossref